Skip to main content

Advertisement

SpringerLink
Log in

Three-Year Oral Clodronate Treatment Does Not Impair Mineralization of Newly Formed Bone—A Histomorphometric Study

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

Bisphosphonates have been used successfully in the treatment of malignant hypercalcemia and skeletal metastases. Recently, clodronate has been studied in adjuvant settings in primary breast cancer. However, long-term effect of adjuvant clodronate on bone histology has not been reported, whereas bone mineral density studies have been published. The aim of this study was to examine the effect and safety of long-term clodronate treatment on bone quality as measured by histomorphometric techniques from bone biopsies. A total of 299 patients with early stage breast cancer were randomized to receive adjuvant oral clodronate (1.6 g/day) or to a control group for 3 years. All patients had adjuvant treatment: premenopausal women had six cycles of chemotherapy and postmenopausal women had antiestrogen for 3 years. Trabecular bone quality was examined in transiliac bone biopsy specimens by using histomorphometric techniques in 28 clodronate treated and 35 control patients who were disease-free at 3 years and who allowed the biopsy specimen to be obtained. No statistically significant differences were found in the values of osteoid, mineral apposition rate, or mineralization lag time in bone biopsies between the clodronate and the control groups. Postmenopausal women who received two antiresorptive drugs, antiestrogen and clodronate, developed features of secondary hyperparathyroidism with increased eroded surface and osteoclast number. In premenopausal, women clodronate with adjuvant chemotherapy, which induced early menopause and rapid bone loss in most of the patients, seemed to conduct slight depression in bone formation. Three-year oral clodronate treatment does not impair mineralization of newly formed bone: however, clodronate with different adjuvant breast cancer treatments has a diverse impact on bone histomorphometry depending on the type of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. I Elomaa C Blomqvist P Gröhn L Porkka AL Kairento K Selander C Lamberg-Allardt T Holmstrom (1983) ArticleTitleLong-term controlled trial with diphosphonate in patients with osteolytic bone metastases Lancet 1 146–149 Occurrence Handle10.1016/S0140-6736(83)92755-1 Occurrence Handle6130197

    Article  PubMed  Google Scholar 

  2. B Kristensen B Ejlertsen M Groenvold S Hein H Loft HT Mouridsen (1999) ArticleTitleOral clodronate in breast cancer patients with bone metastases: a randomized study J Intern Med 246 IssueID1 67–74 Occurrence Handle10.1046/j.1365-2796.1999.00507.x Occurrence Handle10447227

    Article  PubMed  Google Scholar 

  3. AH Paterson TJ Powles JA Kanis E McCloskey J Hanson S Ashley (1993) ArticleTitleDouble-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer J Clin Oncol 11 59–65 Occurrence Handle8418243

    PubMed  Google Scholar 

  4. PF Conte J Latreille L Mauriac F Calabresi R Santos D Campos J Bonneterre G Francini JM Ford (1996) ArticleTitleDelay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial J Clin Oncol 14 2552–2559 Occurrence Handle8823335

    PubMed  Google Scholar 

  5. GN Hortobagyi RL Theriault A Lipton L Porter D Blayney C Sinoff H Wheeler JF Simeone JJ Seaman RD Knight M Heffernan K Mellars DJ Reitsma (1998) ArticleTitleLong-term prevention of skeletal complications of metastatic breast cancer with pamidronate J Clin Oncol 16 2038–2044 Occurrence Handle9626201

    PubMed  Google Scholar 

  6. RL Theriault A Lipton GN Hortobagyi R Leff S Gluck JF Stewart S Costello I Kennedy J Simeone JJ Seaman RD Knight K Mellars M Heffernan DJ Reitsma (1999) ArticleTitlePamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial J Clin Oncol 17 846–854 Occurrence Handle10071275

    PubMed  Google Scholar 

  7. R Hultborn S Gundersen S Ryden E Holmberg J Carstensen UB Wallgren S Killany L Andreassen G Carlsson N Fahl T Hatschek HH Sommer Y Hessman B Hornmark-Stenstam S Johnsborg R Klepp R Laino LG Niklasson CM Rudenstam A Sundbeck M Soderberg G Tejler (1999) ArticleTitleEfficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study Anticancer Res 19 IssueID4C 3383–3392 Occurrence Handle10629624

    PubMed  Google Scholar 

  8. LS Rosen D Gordon M Kaminski LS Rosen D Gordon M Kaminski A Howell A Belch J Mackey J Apffelstaedt M Hussein RE Coleman DJ Reitsma JJ Seaman BL Chen Y Ambros (2001) ArticleTitleZoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial Cancer J 7 IssueID5 377–387 Occurrence Handle11693896

    PubMed  Google Scholar 

  9. I Diel E Solomayer SD Costa C Gollan R Goerner D Wallwiener M Kaufmann G Bastert (1998) ArticleTitleReduction in new metastases in breast cancer with adjuvant clodronate treatment N Engl J Med 339 157–363 Occurrence Handle10.1056/NEJM199808063390601

    Article  Google Scholar 

  10. T Powles S Paterson JA Kanis E McCloskey S Ashley A Tidy K Rosenqvist I Smith L Ottestad S Legault M Pajunen A Nevantaus E Mannisto A Suovuori S Atula J Nevalainen L Pylkkanen (2002) ArticleTitleRandomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer J Clin Oncol 20 IssueID15 3219–3224 Occurrence Handle10.1200/JCO.2002.11.080 Occurrence Handle12149294

    Article  PubMed  Google Scholar 

  11. T Saarto C Blomqvist P Virkkunen I Elomaa (2001) ArticleTitleAdjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial J Clin Oncol 19 IssueID1 10–17 Occurrence Handle11134190

    PubMed  Google Scholar 

  12. T Saarto C Blomqvist M Välimäli P Mäkelä I Elomaa (1997) ArticleTitleChemical castration induced by adjuvant CMF chemotherapy causes a rapid bone loss which is reduced by clodronate. A randomised study in pre-menpausal breast cancer women J Clin Oncol 15 1341–1347 Occurrence Handle9193325

    PubMed  Google Scholar 

  13. L Vehmanen T Saarto I Elomaa P Mäkelä M Välimäki C Blomqvist (2001) ArticleTitleLong-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment” Eur J Cancer 37 IssueID18 2373–2378 Occurrence Handle10.1016/S0959-8049(01)00317-3 Occurrence Handle11720830

    Article  PubMed  Google Scholar 

  14. T Saarto C Blomqvist M Välimäki P Makela S Sarna I Elomaa (1997) ArticleTitleClodronate improves bone mineral density in postmenopausal breast cancer women treated with adjuvant antiestrogens Br J Cancer 75 602–605 Occurrence Handle9052418

    PubMed  Google Scholar 

  15. RG Russell MJ Rogers (1999) ArticleTitleBisphosphonates: from the laboratory to the clinic and back again Bone 25 IssueID1 97–106 Occurrence Handle10.1016/S8756-3282(99)00116-7 Occurrence Handle10423031

    Article  PubMed  Google Scholar 

  16. JR Green P Clezardin (2002) ArticleTitleMechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis Am J Clin Oncol 25 IssueID6 Suppl 1 S3–S9 Occurrence Handle10.1097/00000421-200212001-00002 Occurrence Handle12562045

    Article  PubMed  Google Scholar 

  17. EV McCloskey JA Yates MN Beneton J Galloway S Harris JA Kanis (1987) ArticleTitleComparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man Bone 8 IssueIDSuppl 1 S35–41 Occurrence Handle2825741

    PubMed  Google Scholar 

  18. T Taube I Elomaa C Blomqvist MN Beneton JA Kanis (1993) ArticleTitleComparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study Eur J Cancer 29A IssueID12 1677–1681 Occurrence Handle10.1016/0959-8049(93)90103-M Occurrence Handle8398293

    Article  PubMed  Google Scholar 

  19. BF Boyce L Smith I Fogelman E Johnston S Ralston IT Boyle (1994) ArticleTitleFocalosteomalacia due to low-dose diphosphonate therapy in Paget’s disease Lancet 1 IssueID8381 821–824

    Google Scholar 

  20. BB Adamson SJ Gallacher J Byars SH Ralston IT Boyle BF Boyce (1993) ArticleTitleMineralisation defects with pamidronate therapy for Paget’s disease Lancet 342 IssueID8885 1459–1460 Occurrence Handle10.1016/0140-6736(93)92935-M Occurrence Handle7902484

    Article  PubMed  Google Scholar 

  21. SJ Wimalawansa (1995) ArticleTitleCombined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study Am J Med 99 IssueID1 36–42 Occurrence Handle10.1016/S0002-9343(99)80102-8 Occurrence Handle7598140

    Article  PubMed  Google Scholar 

  22. SL Ruggiero B Mehrotra TJ Rosenberg SL Engroff (2004) ArticleTitleOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases J Oral Maxillofac Surg 62 IssueID5 527–534 Occurrence Handle10.1016/j.joms.2004.02.004 Occurrence Handle15122554

    Article  PubMed  Google Scholar 

  23. JE Aarola AR Johnson JA Kanis BA Oakley P O'Higgins SK Paxton (1992) ArticleTitleAn automated method for the analysis of trabecular bone structure. Comput Biomed Res 25 1–16 Occurrence Handle10.1016/0010-4809(92)90031-5 Occurrence Handle1547623

    Article  PubMed  Google Scholar 

  24. T Saarto C Blomqvist J Risteli L Risteli I Elomaa (1998) ArticleTitleAminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and postmenopausal non metastatic breast cancer patients Br J Cancer 78 IssueID2 240–245 Occurrence Handle9683300

    PubMed  Google Scholar 

  25. B Zegels R Eastell RG Russell D Ethgen I Roumagnac J Collette JY Reginster (2001) ArticleTitleEffect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis Bone 28 108–112 Occurrence Handle10.1016/S8756-3282(00)00410-5 Occurrence Handle11165950

    Article  PubMed  Google Scholar 

  26. SL Greenspan S Holland L Maitland-Ramsey M Poku A Freeman W Yuan U Kher B Gertz (1996) ArticleTitleAlendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy Proc Assoc Am Phys 108 IssueID3 230–238 Occurrence Handle8774056

    PubMed  Google Scholar 

  27. PD Delmas MC Chapuy C Vignon S Charhon D Briancon C Alexandre C Edouard PJ Meunier (1982) ArticleTitleLong term effects of dichloromethylene diphosphonate in Paget’s disease of bone J Clin Endocrinol Metab 54 IssueID4 837–844 Occurrence Handle6460781

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Helsinki University Central Hospital, P.O BOX 180, 00029-HUCH, Helsinki, Finland

    T. Saarto, C. Blomqvist, L. Vehmanen & I. Elomaa

  2. Leiras Clinical Research, Helsinki, Finland

    T. Taube

Authors
  1. T. Saarto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Taube
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Blomqvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Vehmanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Elomaa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Saarto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saarto, T., Taube, T., Blomqvist, C. et al. Three-Year Oral Clodronate Treatment Does Not Impair Mineralization of Newly Formed Bone—A Histomorphometric Study. Calcif Tissue Int 77, 84–90 (2005). https://doi.org/10.1007/s00223-004-0262-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-004-0262-2

Keywords

Search

Navigation